2
|
Kim H, Hwang B, Cho S, Kim WJ, Myung SC, Choi YH, Kim WJ, Lee S, Moon SK. The ethanol extract of Cyperus exaltatus var. iwasakii exhibits cell cycle dysregulation, ERK1/2/p38 MAPK/AKT phosphorylation, and reduced MMP-9-mediated metastatic capacity in prostate cancer models in vitro and in vivo. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2023; 114:154794. [PMID: 37011419 DOI: 10.1016/j.phymed.2023.154794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Revised: 03/24/2023] [Accepted: 03/28/2023] [Indexed: 06/19/2023]
Abstract
BACKGROUND Prostate cancer is the second most common cause of cancer death worldwide in men. The development of novel and highly efficient therapeutic strategies is strongly recommended to treat prostate cancer. Cyperaceae are an ecologically and economically important family of plants with several pharmacological effects. However, the biological efficacy of Cyperus exaltatus var. iwasakii (CE) is unknown. PURPOSE This study aimed to investigate the antitumor effect of the ethanol extract of CE against prostate cancer. METHODS In vitro antitumor efficacy of CE was explored by the MTT assay, cell counting assay, FACS analysis, immunoblot, wound-healing migration, invasion assay, zymographic assay, and EMSA in prostate cancer cells, DU145 and LNCaP. For in vivo experiments, xenograft mice were injected with LNCaP cells. Histology (H&E and Ki-67) and biochemical enzyme assay were then performed. The toxicity test was evaluated by an acute toxicity assay. The phytochemical constituents of CE were identified by spectrometric and chromatographic analyses. RESULTS CE exerted a significant antiproliferative effect against prostate cancer cells. CE-induced antiproliferative cells were associated with cell cycle arrest at G0/G1 (cyclin D1/CDK4, cyclin E/CDK2, p21Waf1) in DU145 cells, but G2/M (ATR, CHK1, Cdc2, Cdc25c, p21Waf1, and p53) in LNCaP cells. CE stimulated the phosphorylation of ERK1/2, p38 MAPK, and AKT in DU145 cells, but only p38 MAPK phosphorylation was increased in LNCaP cells. CE treatment suppressed migration and invasion in the two types of prostate cancer cells by inhibiting MMP-9 activity through the regulation of transcription factors, such as AP-1 and NF-κB. In vivo experiments showed a reduction in tumor weight and size following oral CE administration. Histochemistry confirmed that CE inhibited tumor growth in the mouse LNCaP xenograft model. The administration of CE had no adverse effects on body weight, behavioral patterns, blood biochemistry, and histopathology findings of vital organs in mice. Finally, a total of 13 phytochemical constituents were identified and quantified in CE. The most abundant secondary metabolites in CE were astragalin, tricin, and p-coumaric acid. CONCLUSION Our results demonstrated the antitumor efficacy of CE against prostate cancer. These findings suggest that CE might be a potential candidate for prostate cancer prevention or treatment.
Collapse
Affiliation(s)
- Hoon Kim
- Department of Food and Nutrition, Chung-Ang University, 4726 Seodong-Daero, Daedeok-Myeon, Anseong 17546, Republic of Korea
| | - Byungdoo Hwang
- Department of Food and Nutrition, Chung-Ang University, 4726 Seodong-Daero, Daedeok-Myeon, Anseong 17546, Republic of Korea
| | - Seongbin Cho
- Department of Food and Nutrition, Chung-Ang University, 4726 Seodong-Daero, Daedeok-Myeon, Anseong 17546, Republic of Korea
| | - Woo Jung Kim
- Biocenter, Gyeonggido Business and Science Accelerator, Suwon 16229, Republic of Korea
| | - Soon Chul Myung
- Department of Urology, College of Medicine, Chung-Ang University, Seoul 06974, Republic of Korea
| | - Yung Hyun Choi
- Department of Biochemistry, College of Oriental Medicine, Dongeui University, Busan 47340, Republic of Korea
| | - Wun-Jae Kim
- Institute of Urotech, Cheongju, Chungcheongbuk-do 361-763, Republic of Korea
| | - Sanghyun Lee
- Department of Plant Science and Technology, Chung-Ang University, 4726 Seodong-Daero, Daedeok-Myeon, Anseong 17546, Republic of Korea.
| | - Sung-Kwon Moon
- Department of Food and Nutrition, Chung-Ang University, 4726 Seodong-Daero, Daedeok-Myeon, Anseong 17546, Republic of Korea.
| |
Collapse
|
7
|
Moreira-Silva F, Henrique R, Jerónimo C. From Therapy Resistance to Targeted Therapies in Prostate Cancer. Front Oncol 2022; 12:877379. [PMID: 35686097 PMCID: PMC9170957 DOI: 10.3389/fonc.2022.877379] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Accepted: 04/25/2022] [Indexed: 12/12/2022] Open
Abstract
Prostate cancer (PCa) is the second most common malignancy among men worldwide. Although early-stage disease is curable, advanced stage PCa is mostly incurable and eventually becomes resistant to standard therapeutic options. Different genetic and epigenetic alterations are associated with the development of therapy resistant PCa, with specific players being particularly involved in this process. Therefore, identification and targeting of these molecules with selective inhibitors might result in anti-tumoral effects. Herein, we describe the mechanisms underlying therapy resistance in PCa, focusing on the most relevant molecules, aiming to enlighten the current state of targeted therapies in PCa. We suggest that selective drug targeting, either alone or in combination with standard treatment options, might improve therapeutic sensitivity of resistant PCa. Moreover, an individualized analysis of tumor biology in each PCa patient might improve treatment selection and therapeutic response, enabling better disease management.
Collapse
Affiliation(s)
- Filipa Moreira-Silva
- Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (He-alth Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC), Porto, Portugal
| | - Rui Henrique
- Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (He-alth Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC), Porto, Portugal.,Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.,Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences of the University of Porto (ICBAS-UP), Porto, Portugal
| | - Carmen Jerónimo
- Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (He-alth Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC), Porto, Portugal.,Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences of the University of Porto (ICBAS-UP), Porto, Portugal
| |
Collapse
|
8
|
Herrero-Aguayo V, Sáez-Martínez P, Jiménez-Vacas JM, Moreno-Montilla MT, Montero-Hidalgo AJ, Pérez-Gómez JM, López-Canovas JL, Porcel-Pastrana F, Carrasco-Valiente J, Anglada FJ, Gómez-Gómez E, Yubero-Serrano EM, Ibañez-Costa A, Herrera-Martínez AD, Sarmento-Cabral A, Gahete MD, Luque RM. Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool. MOLECULAR THERAPY. NUCLEIC ACIDS 2022; 27:1164-1178. [PMID: 35282415 PMCID: PMC8889365 DOI: 10.1016/j.omtn.2022.02.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Accepted: 02/10/2022] [Indexed: 04/12/2023]
Abstract
Prostate-specific antigen (PSA) is the gold-standard marker to screen prostate cancer (PCa) nowadays. Unfortunately, its lack of specificity and sensitivity makes the identification of novel tools to diagnose PCa an urgent medical need. In this context, microRNAs (miRNAs) have emerged as potential sources of non-invasive diagnostic biomarkers in several pathologies. Therefore, this study was aimed at assessing for the first time the dysregulation of the whole plasma miRNome in PCa patients and its putative implication in PCa from a personalized perspective (i.e., obesity condition). Plasma miRNome from a discovery cohort (18 controls and 19 PCa patients) was determined using an Affymetrix-miRNA array, showing that the expression of 104 miRNAs was significantly altered, wherein six exhibited a significant receiver operating characteristic (ROC) curve to distinguish between control and PCa patients (area under the curve [AUC] = 1). Then, a systematic validation using an independent cohort (135 controls and 160 PCa patients) demonstrated that miR-107 was the most profoundly altered miRNA in PCa (AUC = 0.75). Moreover, miR-107 levels significantly outperformed the ability of PSA to distinguish between control and PCa patients and correlated with relevant clinical parameters (i.e., PSA). These differences were more pronounced when considering only obese patients (BMI > 30). Interestingly, miR-107 levels were reduced in PCa tissues versus non-tumor tissues (n = 84) and in PCa cell lines versus non-tumor cells. In vitro miR-107 overexpression altered key aggressiveness features in PCa cells (i.e., proliferation, migration, and tumorospheres formation) and modulated the expression of important genes involved in PCa pathophysiology (i.e., lipid metabolism [i.e., FASN] and splicing process). Altogether, miR-107 might represent a novel and useful personalized diagnostic and prognostic biomarker and a potential therapeutic tool in PCa, especially in obese patients.
Collapse
Affiliation(s)
- Vicente Herrero-Aguayo
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14014 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), 28019 Madrid, Spain
| | - Prudencio Sáez-Martínez
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14014 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), 28019 Madrid, Spain
| | - Juan M. Jiménez-Vacas
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14014 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), 28019 Madrid, Spain
| | - M. Trinidad Moreno-Montilla
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14014 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), 28019 Madrid, Spain
| | - Antonio J. Montero-Hidalgo
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14014 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), 28019 Madrid, Spain
| | - Jesús M. Pérez-Gómez
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14014 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), 28019 Madrid, Spain
| | - Juan L. López-Canovas
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14014 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), 28019 Madrid, Spain
| | - Francisco Porcel-Pastrana
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14014 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), 28019 Madrid, Spain
| | - Julia Carrasco-Valiente
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Urology Service, HURS/IMIBIC, 14004 Córdoba, Spain
| | - Francisco J. Anglada
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Urology Service, HURS/IMIBIC, 14004 Córdoba, Spain
| | - Enrique Gómez-Gómez
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Urology Service, HURS/IMIBIC, 14004 Córdoba, Spain
| | - Elena M. Yubero-Serrano
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), 28019 Madrid, Spain
- Lipids and Atherosclerosis Unit, HURS/IMIBIC, 14004 Córdoba, Spain
| | - Alejandro Ibañez-Costa
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14014 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), 28019 Madrid, Spain
| | - Aura D. Herrera-Martínez
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Endocrinology and Nutrition Service, HURS/IMIBIC, 14004 Córdoba, Spain
| | - André Sarmento-Cabral
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14014 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), 28019 Madrid, Spain
| | - Manuel D. Gahete
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14014 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), 28019 Madrid, Spain
- Corresponding author Manuel D. Gahete, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain.
| | - Raúl M. Luque
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain
- Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14014 Córdoba, Spain
- Hospital Universitario Reina Sofía (HURS), 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), 28019 Madrid, Spain
- Corresponding author Raúl M. Luque, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Edificio IMIBIC, Av. Menéndez Pidal s/n, 14004 Córdoba, Spain.
| |
Collapse
|